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Abstract: Measurements of magneto-optical relaxation signals of magnetic nanoparticles 
functionalized with biomolecules are a novel biosensing tool. Upon transmission of a laser 
beam through a nanoparticle suspension in a pulsed magnetic field, the properties of the 
laser beam change. This can be detected by optical methods. Biomolecular binding events 
leading to aggregation of nanoparticles are ascertainable by calculating the relaxation time 
and from this, the hydrodynamic diameters of the involved particles from the optical 
signal. Interaction between insulin-like growth factor 1 (IGF-1) and its antibody was 
utilized for demonstration of the measurement setup applicability as an immunoassay. 
Furthermore, a formerly developed kinetic model was utilized in order to determine kinetic 
parameters of the interaction. Beside utilization of the method as an immunoassay it can be 
applied for the characterization of diverse magnetic nanoparticles regarding their size and 
size distribution. 
Keywords:  magnetic nanoparticles; magneto-optical relaxation; immunoassay; IGF-1 
assay 
 
1. Introduction 
 
Since the first utilization of gold nanoparticles in an immunoassay for human chorionic 
gonadotrophin in the form of a pregnancy test in 1980 [1], nanomaterials are an inherent part of 
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immunological methods. Currently, nanomaterials include quantum dots and metallic nanoparticles as 
improved labels as well as optical reporters. Nanowires as label-free biosensors and superparamagnetic 
nanoparticles are used for magnetic separation of biomolecules. The latter were applied in 
heterogeneous (e.g. enzyme linked immunosorbent assays – ELISAs) [2,3] or homogeneous 
immunoassays, where signals are detected magnetically by superconducting quantum interference 
devices (SQUIDs) [4,5], fluxgate sensors [6] or susceptibility measurements [7].  
Biosensor systems based on biomolecular recognition are the most widely used analytical 
technology in biodiagnostics, including the determination of antigens, hormones and drugs by means 
of antibody application [8]. Antibodies offer quality characteristics, which predestine them for the 
application in immunoassays: the selectivity to bind to an extremely high variety of molecules, cells or 
viruses, the high binding specificity and the high bond strength between antibody and antigen. Since 
nanotechnology found its way into bioanalytical methods, analyses on a minimized scale are possible, 
which allows for simultaneous detection of numerous analytes and reduced sample volumes.  
This contribution concentrates on a homogeneous immunoassay of insulin like growth factor 1 
(IGF-1) and its polyclonal antibody anti-IGF-1 with magnetic nanoparticles (MNPs) as signal 
generators. IGF-1 (7.7 kDa) is the most important peripheral mediator of growth hormone action [9] 
and it is mainly synthesized in the liver in response to growth hormone stimulation [10]. It has been 
found that the risk of cancer, diabetes and acromegaly is higher among people with raised blood levels 
of IGF-1 [11,12]. Thus, determination of IGF-1 levels for diagnosis of these diseases and monitoring 
during therapy is of crucial importance. 
For this purpose iron oxide core-shell-nanoparticles were functionalized with antibodies. The 
appropriate antigen was added in different amounts. An increase in particle diameter as a consequence 
of nanoparticle aggregation due to the antigen-antibody-interaction was observed by the measurement 
of the relaxation time of MNPs before aligned in an external magnetic field. Particle relaxation 
generates a change in the polarization state of a laser beam, which is propagated through the ferrofluid. 
This optical signal is detected by a photodiode. The measurement setup allows the simple and fast 
determination of biomolecular binding events due to the explicit relaxation time detection of only 
magnetic particles. Interaction analyses are possible in any media and body fluids. Time consuming 
washing steps are not required [13].  
In addition, kinetic parameters such as the interaction rate constants and the equilibrium constant 
KD of the underlying protein interactions can be calculated in comprehension with an ad hoc developed 
kinetic model [14]. In this model we assume a chain like aggregation of MNPs due to antigen-antibody 
reaction. From the known antigen concentration added to the magnetic antibody sensors and the 
particle sizes increasing during protein interaction we are able to calculate the unknown parameters KD 
and the antibody amount bound on MNPs by means of a scaled plot. However, in principle any 
biomolecular binding system can be analyzed by the described method. 
Beside the application of the method as a homogeneous immunoassay, it can be utilized for the 
characterization of diverse MNPs concerning their mean particle size and size distribution without 
laborious sample preparation. Sensors 2009, 9                
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2. Experimental Section 
 
2.1. Magnetic Nanoparticles 
 
For the immunometric assay described herein DDM128N nanoparticles (Meito Sangyo, Japan) were 
selected. They are composed of a maghemite core and a carboxydextran shell. In addition to mean size 
and size distribution measurements by measurements of the magneto-optical relaxation of ferrofluids 
(MORFF) and dynamic light scattering measurements (photon correlation spectroscopy, PCS), 
particles were characterized by PCS measurements with respect to their stability, as determined by the 
zeta potential in diverse media [water, phosphate buffer 10 mM pH 7.4, phosphate buffered saline 
(PBS) and human plasma]. 
Since MNPs possess a wide size distribution they were separated in different size fractions by 
magnetic fractionation. This was done by means of an adjustable electromagnet (Bruker, Germany) 
and MACS LS columns (Miltenyi Biotec, Germany). For the next preparation steps only MNPs of the 
largest fraction with a mean hydrodynamic diameter of about 55 nm were utilized. 
Functionalization of the particles was achieved by reductive amination. As functionalization agent 
streptavidin (IBA GmbH, Germany) was applied as it forms extremely stable complexes with biotin. 
Subsequently one of the interaction partners can be biotinylated and than easily connected with the 
streptavidinated MNPs [13,14]. Furthermore, direct coupling of protein interaction partners on MNPs 
by the periodate method was successful as well. Here, biotinylated polyclonal anti-IGF-1 antibody (US 
Biologicals, USA) was conjugated with the manufactured streptavidin-MNPs. For this purpose, 50 µg 
of the antibody were diluted in 6 mL PBS under sterile working conditions followed by the dropwise 
addition of 500 µL of the streptavidin-MNPs. After incubation for 2 h at 4 °C, 100 µg biotin were 
added in order to saturate the remaining streptavidin binding sites. After another hour, MNPs were 
washed via a MACS LS column in a static magnetic field. 
 
2.2. Magneto-optical Relaxation Measurements of Ferrofluids  
 
2.2.1. Measurement Setup 
 
Suspensions of magnetic nanoparticles are superparamagnetic. That means that they do not offer 
remanence without an external magnetic field. In the presence of an external magnetic field the 
particles align along the field direction and relax due to Brownian motion after removing the field. 
Magneto-optical relaxation measurements are performed by means of magnetic incitation of MNPs 
and subsequent detection of the relaxation time by a generated optical signal. For this purpose a laser 
(wavelength 635  nm), a polarizer, a magnetizing coil, a quarterwave plate, an analyzer and a 
photodiode as the detector are arranged on an optical bench (Figure 1). 
Inside the magnetizing coil the cuvette with suspended MNPs is placed. As ferrofluids become 
anisotropic in the presence of a magnetic field birefringence of the impinged laser beam is generated 
(Cotton-Mouton-effect) [15]. After switching off the magnetic field the birefringence relaxes similarly 
to the MNPs due to Brownian motion. The decay of the birefringence is detected as decreasing light 
intensity by the photo diode. The signal is converted into a voltage by a low noise current amplifier. Sensors 2009, 9                
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Assuming monodisperse particles the decay of the birefringence can be described as a light intensity 
I(t) by: 
] / exp[ ) ( 0 B t I t I      (1) 
with  B  being the Brownian relaxation time. 
Figure 1. Measurement setup of MORFF. 
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First of all, particle sizes are determinable with this setup as the relaxation time  B   is  mainly 
dependent on the hydrodynamic particle diameter dhyd according to the Brownian equation:  
kT
dhyd
B 6
3 
    (2) 
with   being the viscosity of the medium and kT the thermal energy. Particle sizes determined by 
MORFF are in good accordance with sizes generated by dynamic light scattering measurements and 
plausible when compared with atomic force microscopy (AFM) [16].  
Besides mean hydrodynamic diameters the size distribution P(dhyd) of particle systems can be 
determined. The superposition of signals from MNPs with different relaxation times results in: 
    . d ) ( )] ( / exp[ ) ( ) ( 0 hyd hyd hyd hyd d d P d t d I t I    (3) 
Applying a log-normal distribution function:  
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parameters μ and σ, describing the diameter of the distribution center and the distribution width, can be 
calculated. Fitting the experimental relaxation curve with the size distribution function (Equations 3 
and 4) results in a better conformance of experimental and fitting curve, which shows that the particle 
diameters in the ferrofluid are size distributed MNPs and not monodisperse (Figure 2).  Sensors 2009, 9                
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Figure 2. Normalized relaxation data of DDM128N particles of 55 nm in diameter (black) 
fitted with monoexponential decay (green) and size distribution function (red). 
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2.2.2. Monitoring Antibody-Antigen Interactions 
 
In addition, this method can be utilized for the detection of biomolecular interactions concerning 
quality and kinetic aspects in the manner of a homogeneous immunoassay. A suspension of anti-IGF-1 
sensors with an iron content of about 0.1 µM were diluted 10-fold in phosphate buffer 10 mM, pH 7.4, 
PBS or human plasma (10%) to a final volume of 1 mL in a glass cuvette. Different amounts of IGF-1 
antigen were added. Data were acquired every minute for 2 h. In order to exclude unspecific binding 
reactions, an addition of 3 nM bovine serum albumin instead of antigen served as a control.  
 
2.3. Kinetic Model for Immunometric Analyses with MORFF 
 
The binding affinity between antigen (A) and antibody (B) is usually described with association and 
dissociation rate constants ka and kd, or with the equilibrium constant KD. These quantities are   
defined by: 
AB
B A
a
d
D c
c c
k
k
K   ,  (5) 
where cA and cB denotes the concentration of unbound interaction partners and cAB the bound ones. 
These concentrations cannot be measured directly in our experimental setup; instead the binding 
reaction can be characterized by the rate and end value of particle growth caused by the aggregation of 
MNPs. In order to calculate the kinetic parameters a model of chain-like aggregation of the particles 
was developed. Antibody loaded MNPs are linked via the antigen molecules to chains of the form  
…-[A-A]-[B-B]-[A-A]-[B-B]-…. Two antibodies B on the same MNP are symbolized by [B-B], 
whereas [A-A] denotes the antigen molecule with two binding sites (epitopes) A. From the known 
antigen amount added to antibody sensors and the increase in particle size during the interaction the 
unknown parameters can be estimated using theoretical concepts of stepwise polymerization. A more 
detailed description of our model is given in [14]. Sensors 2009, 9                
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Relating the normalized mean particle diameter in steady state (90 – 120 min incubation time) 
SS SS SS d d D 1 /   (d
SS
1 – diameter of a single MNP) to the weight-average of chain length distribution 
the equation: 
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with cA,0 being the epitope concentration and cB,0 the antibody binding sites on MNP at the reaction 
start can be obtained.  
For the scaled plot suggested here, the mean diameters 
SS d , determined by the exponential fit 
(Equation 1) of the relaxation signals of various antigen concentrations under steady state conditions, 
have to be normalized by the initial value d
SS
1 to obtain D
SS. Plotting the quantity: 
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against the respective antigen concentrations cA,0 a linear regression in form of  b ax y    can  be 
performed.  
The equilibrium constant KD and the antibody concentration cB,0 result from the regression   
parameters as: 
,
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3. Results and Discussion 
 
3.1. Characterization of DDM128N 
 
The mean hydrodynamic diameter of the original ferrofluid is about 45 nm. For the application in 
immunological analyses DDM128N was fractionated into five fractions by magnetic fractionation. 
Since only the largest particles give a sufficient relaxation signal, the particles of this fraction were 
used. In Figure 3 size distributions of the original and the largest fraction of DDM128N are depicted. 
The mean hydrodynamic diameter of the last is about 55 nm.  
Figure 3. Size distributions of the original DDM128N (black) and the largest fraction (red). 
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The zeta potential as a stability marker generated by PCS in different media averaged out at -35 mV 
in water, -29 mV in phosphate buffer pH 7.4 10 mM, -27 mV in 0.9% NaCl solution, -0.4 mV in PBS 
and -2.3 mV in 10% human plasma. Stability of the particle suspension decreases with increasing ion 
and protein concentrations due to the electrostatic interference of repulsive forces between MNPs.  
 
3.2. IGF-1/anti-IGF-1 Binding Assay 
 
In Figure 4 the increase in the hydrodynamic diameter as a consequence of the addition of antigen 
to antibody sensors is depicted. The hydrodynamic diameters of aggregates developing during the 
interaction were determined by the monoexponential fit (Equation 1). Over a period of 120  min 
concentrations of 6.6 nM and higher IGF-1 generated an aggregate size growth up to 1.5-fold of the 
original particle size. As the diameter increases fast during the first 30 min, a slower part follows. 
Control experiments include the incubation of antibody sensors with BSA in order to exclude 
unspecific binding. In this case, MNP diameters remained constant. Steady state conditions are 
achieved within 90 – 120 min. 
Figure 4. Normalized mean hydrodynamic diameter determined by monoexponential fit of 
relaxation data of the interaction between anti-IGF-1-MNPs and IGF-1 in different 
amounts. Control: 3 nM BSA. 
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3.3. Kinetic Aspects of the IGF-1/Anti-IGF-1 Interaction 
 
Among the qualitative determination of the IGF-1/anti-IGF-1 binding reaction in form of the 
binding assays the kinetic aspects received priority. The knowledge of interaction rates and affinities 
facilitate the identification and characterization of antibodies and other proteins, e.g. in high 
throughput screening methods in search of new drugs, where affinity methods are applied [20].  
The equilibrium constant KD was determined by creating a scaled plot. In contrast to the usual 
immunoassay techniques, where the fractions of bound and free reaction partners can be presented in a 
linearized plot (e.g. Scatchard plot), these quantities are not directly ascertainable with this method. 
The known parameters total antigen concentration and particle size increase due to the formation of 
aggregates are included in the data evaluation. The model acts on the assumption of the formation of a 
chain like topology of particle aggregates. Up to trimers the involved MNPs have no alternative for Sensors 2009, 9                
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aggregate formation. With the formation of tetramers the possibility of branching is given. That means 
that the developed model is only valid for small reaction conversions.  
In Figure 5 the scaled plot for the interaction between IGF-1 and its antibody is depicted as the 
conversion parameter y versus the concentration of IGF-1 epitopes. The conversion parameter is 
composed of the underlying steady state diameters averaged from diameters at t = 90 - 120 min and the 
epitope concentration. The equilibrium constant KD was calculated as described in Section 2.3. and 
totals 70 nM. The antibody loading on MNPs cB,0 was estimated as 78 nM. 
Figure 5. Scaled plot for the interaction between IGF-1 and the antibody sensors. 
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The formation of MNP chains is already described in literature. Chantrell et al. [21] demonstrated 
chain formation under influence of an external magnetic field. However, also without magnetic fields 
chain like aggregates due to magneto-statical interactions are described by Klokkenburg et al. [22]. 
Although protein binding plays the important role in aggregate formation in this contribution magnetic 
dipole-dipole interaction cannot be excluded.  
A further prerequisite for the model validity is that only two antibody binding sites on each MNP 
are involved in the binding process as well as two epitopes per antigen. Former investigations 
concerning the determination of effective binding sites on functionalized MNPs result in the 
calculation of 1 – 10 binding sites assuming a particle core diameter of 10  nm [14]. Thus, the 
assumption of two binding sites is in the right size range.  
Modelling of the aggregate formation plays also an important role. We assume an additive increase 
in diameters, i.e. dimers possess the twofold diameter of monomers, etc. Today we are not able to 
substantiate the actual aggregate topology. For a further clarification of the aggregate relaxation 
behaviour additional investigations are required enabling a more concise description of the aggregate 
behaviour, e.g. size exclusion chromatography ore magnetic fractionation. 
The equilibrium constant describing the affinity between antigen and antibody was also determined 
by other workgroups with different immunometric methods. Manes et al. [23] calculated a KD of 0.1 – 
100 nM for IGF-1 and monoclonal antibodies on the basis of BIAcore
TM SPR interaction analyses. 
Another group determined equilibrium constants of 0.01 – 0.15  nM for the interaction between 
monoclonal anti-IGF-1 antibodies and an IGF-1-analogue (LR3-IGF-1) by ELISA [24]. SPR analysis 
and also ELISA are methods based on interactions on solid surfaces. First of all MORFF is Sensors 2009, 9                
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representing a solution based method, though immobilization of antibodies on MNPs constrains the 
free movement of proteins. At least a comparison with results from SPR analysis is possible. Day and 
colleagues [25] obtained comparable kinetic data from SPR, isothermal titration calorimetry and 
stopped flow fluorescence, whereas the last two methods are solution based. Furthermore, the dextran 
surface of the SPR sensor chip is not a rigid and solid system, but rather a swollen gel matrix, which 
enables some degree of diffusional rotation of proteins. Binding constants determined by SPR are very 
sensitive of potential artefacts produced by mass transport, non-specific binding and avidity effects 
[26], which require a very accurate and time-consuming sample preparation. The topology of 
interactions should be present previous to the experiments in order to evaluate the data correctly with 
evaluation procedures provided by the BIAcore
TM software.  
Due to the utilization of a polyclonal antibody it is supposable that the KD determined by MORFF 
differs from that in literature. A polyclonal antibody is a blend of diverse antibody subtypes with 
different affinities. We used a polyclonal antibody in our method for demonstration purposes. For 
detection of kinetics with immunoassays, i.e. using antibodies, concrete data for KD are rarely; in fact 
affinity ranges are given (e.g. in [23]). This is due to the numerous method evaluation factors, which 
cannot be directly influenced. Therefore, the estimation of the order of magnitude of KD is satisfying. 
 
3.4. Method Validation 
  
For a prospective utilization in an every day lab routine the method described herein was validated 
according the ICH tripartite guidelines [27] for MNPs as well as for the analyzed protein system. 
Concerning the particle concentration the MORFF technology offers a limit of detection (LOD) of 
100 fmol·mL
-1 particles [14]. Meanwhile other methods offer higher sensitivity regarding particle 
detection; however, our method is more robust and does not require magnetic shielding [28, 29]. 
Furthermore the LOD of the analyzed antigen IGF-1 was determined. Ideally, it should be below the 
physiological and pathological concentrations. In table 1 concentrations of human IGF-1 and the LOD 
are demonstrated.  
Table 1. Physiological and pathological concentrations of IGF-1 in humans (examples) 
and current LOD of MORFF. 
Physiological concentration  Pathological concentration  LOD of MORFF 
Children (before puberty): 130 – 
485 ng/mL [30] 
Adults: 95 – 250 ng/mL [31] 
100 – 150 µg/mL Type 2 
diabetes [32] 
1 – 3 µg/mL traumatic brain 
injuries [33] 
24.2 ng/mL 
 
The results demonstrate that at present we are able to determine adequate physiological and 
pathological IGF-1 concentrations with the method described herein. IGF-1 is detected by other 
workgroups mainly by radioimmunoassays, fluorescence immunoassays, chemiluminescence 
immunoassays or ELISAs. The LOD of these immunoassays is between 0.1 and 100 ng/mL [34,35]. A 
major problem of these immunoassays is the interference of IGF-1 with IGF-1 binding proteins 
(IGFBP), which also appear in plasma samples. Beside elimination of IGF-1/IGFBP-complexes with Sensors 2009, 9                
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acidification processes or acid-ethanol extraction, the addition of IGF-2 is now the method of choice to 
circumvent this problem. IGF-2 binds to IGFBP to the same degree as IGF-1 and blocks binding sites 
on IGFBP for IGF-1, which then can be analyzed undisturbed with high specific antibodies [12]. Of 
course this is of major relevance for the sample preparation of the magneto-optical immunoassay 
described herein. In future experiments, an adequate IGF-2 amount as a sample adjuvant has to be 
evaluated in order to specify the exact IGF-1 concentration.  
In principle the LOD of both, MNPs and protein systems can be decreased by optimization of the 
cuvette geometry concerning the sample volume. A volume of 10 µL would be enough to ensure the 
propagation of the laser beam. Furthermore, the application of more appropriate MNPs offering high 
shape anisotropy, a narrow size distribution and sufficiently large magnetic cores would result in 
higher signals. 
 
4. Conclusions 
 
Measurements of the magneto-optical relaxation of magnetically functionalized antibodies present a 
novel, simple and inexpensive diagnosis tool for the analysis of biomolecular interactions. The method 
can be applied as a homogeneous suspension immunoassay, which can be performed in everyday 
laboratory routines due to its small size and time-saving analysis procedure. Beside interaction 
analyses kinetic parameters for affinity analyses can be calculated by means of a kinetic model. 
Furthermore, the method can be applied for the simple and rapid characterization of diverse magnetic 
nanoparticles regarding their hydrodynamic size and size distribution. 
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